OBJECTIVES: Stereotactic body radiation therapy (SBRT) is a new therapeutic paradigm that uses a very large dose per fraction treatments (ablative hypofractionation). We investigated the use of ablative hypofractionation in treating human renal cell carcinoma using a nude mouse model. METHODS: Nude mice were injected subcutaneously with A498 human renal carcinoma cells. Tumour-bearing animals were radiated with three fractions (one per week) for a total dose of 48 Gy (n = 12), while untreated animals served as controls (n = 7). The mice were weighed, and tumour volumes were measured at baseline and weekly until 7 weeks post-treatment. RESULTS: Control animals demonstrated progressive tumour growth and were sacrificed because of either tumour size or ulceration. Tumours in the treatment group grew to three times their initial size over the 3 weeks of treatment but subsequently decreased progressively to less than 30% of their initial volume. All treated tumours exhibited marked cytologic changes. Tumours from mice sacrificed before post-treatment week 4 had a mitotic count of 1-4/10 hpf. Tumours from mice sacrificed more than 4 weeks post-treatment (n = 4) demonstrated no mitoses. CONCLUSIONS: Treatment with high-dose-per-fraction radiation to 48 Gy resulted in a sustained decrease in tumour volume and marked cytologic changes. These results are preliminary--but promising--and encourage further research into this application of ablative hypofractionated radiation for kidney cancer.
OBJECTIVES: Stereotactic body radiation therapy (SBRT) is a new therapeutic paradigm that uses a very large dose per fraction treatments (ablative hypofractionation). We investigated the use of ablative hypofractionation in treating humanrenal cell carcinoma using a nude mouse model. METHODS:Nude mice were injected subcutaneously with A498 humanrenal carcinoma cells. Tumour-bearing animals were radiated with three fractions (one per week) for a total dose of 48 Gy (n = 12), while untreated animals served as controls (n = 7). The mice were weighed, and tumour volumes were measured at baseline and weekly until 7 weeks post-treatment. RESULTS: Control animals demonstrated progressive tumour growth and were sacrificed because of either tumour size or ulceration. Tumours in the treatment group grew to three times their initial size over the 3 weeks of treatment but subsequently decreased progressively to less than 30% of their initial volume. All treated tumours exhibited marked cytologic changes. Tumours from mice sacrificed before post-treatment week 4 had a mitotic count of 1-4/10 hpf. Tumours from mice sacrificed more than 4 weeks post-treatment (n = 4) demonstrated no mitoses. CONCLUSIONS: Treatment with high-dose-per-fraction radiation to 48 Gy resulted in a sustained decrease in tumour volume and marked cytologic changes. These results are preliminary--but promising--and encourage further research into this application of ablative hypofractionated radiation for kidney cancer.
Authors: Shankar Siva; Gargi Kothari; Alexander Muacevic; Alexander V Louie; Ben J Slotman; Bin S Teh; Simon S Lo Journal: Nat Rev Urol Date: 2017-06-20 Impact factor: 14.432
Authors: Raquibul Hannan; Vitaly Margulis; Stephen G Chun; Nathan Cannon; D W Nathan Kim; Ramzi E Abdulrahman; Arthur Sagalowsky; Ivan Pedrosa; Hak Choy; James Brugarolas; Robert D Timmerman Journal: Cancer Biol Ther Date: 2015 Impact factor: 4.742
Authors: Juliane Hoerner-Rieber; Marciana Duma; Oliver Blanck; Guido Hildebrandt; Andrea Wittig; Fabian Lohaus; Michael Flentje; Frederick Mantel; Robert Krempien; Michael J Eble; Klaus Henning Kahl; Judit Boda-Heggemann; Stefan Rieken; Matthias Guckenberger Journal: J Thorac Dis Date: 2017-11 Impact factor: 2.895
Authors: Bs Teh; C Bloch; M Galli-Guevara; L Doh; S Richardson; S Chiang; P Yeh; M Gonzalez; W Lunn; R Marco; J Jac; Ac Paulino; Hh Lu; Eb Butler; Rj Amato Journal: Biomed Imaging Interv J Date: 2007-01-01
Authors: Michelle A Stinauer; Brian D Kavanagh; Tracey E Schefter; Rene Gonzalez; Thomas Flaig; Karl Lewis; William Robinson; Mark Chidel; Michael Glode; David Raben Journal: Radiat Oncol Date: 2011-04-08 Impact factor: 3.481